甲基脱氧糖化物-多胺组合对抗关键优先级的抗卡巴胺耐药格拉姆阴性细菌
Ana M de Matos1, Patrícia Calado2, Mónica Miranda2
1Centro de Química Estrutural, Institute of Molecular Sciences, Departmento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, 1749-016, Campo Grande, Lisbon, Portugal. amamatos@fc.ul.pt.
Scientific reports
|January 26, 2024
概括
新的基于碳水化合物的化合物显示出对抗耐药性格拉姆阴性细菌的承诺,如耐卡巴尼姆耐药的Acinetobacter baumannii (CRAB),Pseudomonas aeruginosa (CRPA) 和Enterobacteriaceae (CRE). 结合胆固醇素,这些新型糖化物有效地向具有挑战性的感染.
科学领域:
- 药用化学 医学化学
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
背景情况:
- 抗微生物耐药性 (AMR) 的升级需要新型抗菌剂,特别是针对关键的格拉姆阴性病原体.
- 由于外膜 (OM) 透限制,现有的膜破坏剂对抗阴性细菌无效.
- 耐卡巴胺的格拉姆阴性感染 (CRAB,CRPA,CRE) 构成了严重的全球健康威胁.
研究的目的:
- 通过增强OM透性,重新利用基脱氧糖化物对抗阴性细菌.
- 合成和评估新的基于碳水化合物的化合物,包括一个独特的4,6-二氧化碳C-糖化物.
- 评估这些化合物的协同抗微生物活性与polymyxins对抗多药耐药 (MDR) 格拉姆阴性病原体.
主要方法:
- 通过优化的脱氧化合成合成一种新型的基4,6-二氧化碳C-糖化物 (化合物5).
- 对5个参考基脱氧甘油化物和化合物5与次治疗性胆固醇结合的评估.
- 针对CRAB,CRPA和CRE的临床分离物进行抗菌敏感性测试.
- 对人类细胞系的细胞毒性评估 (HEK-293T,Caco-2).
主要成果:
- 大多数测试的葡萄糖类,特别是化合物5,在与胆固醇结合时,对MDR CRAB,CRPA和CRE表现出强烈的活性.
- 化合物5显示出显著的疗效 (MIC 3.1μg/mL与胆固醇素0.5μg/mL对抗CRPA;0.25μg/mL对抗CRAB/CRE).
- 新型化合物对人类细胞系表现出可接受的细胞毒性概况.
结论:
- 这项研究突出了利用碳水化合物基化合物向格兰阴性内膜的潜力.
- 新型的4,6-二氧化碳C-糖化物代表了开发针对MDR格兰氏阴性感染的新疗法的一个有希望的支架.
- 结合疗法与多胺素可以克服OM障碍,增强糖化物抗菌剂的疗效.
相关概念视频
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
309
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
309


